Novo Nordisk A/s

This study tests a new weekly injection called NNC0519-0130 to see if it can safely improve kidney function in people with chronic kidney disease, who may or may not have type 2 diabetes and are overweight or obese. About 465 adults will be randomly assigned to receive the new dr…

This study tests a monthly injection called ziltivekimab in 5,600 people with heart failure and signs of inflammation. The goal is to see if it can prevent heart failure-related deaths, hospital stays, or urgent care visits compared to a placebo. Participants will receive injecti…

This study tests whether a monthly injection of ziltivekimab can reduce the risk of another heart attack, stroke, or heart-related death in people who have recently had a heart attack. About 10,000 participants will receive either the active drug or a placebo for around 2 years. …

This study will follow about 630 people with type 1 diabetes in Japan who are already prescribed Awiqli, a once-weekly medicine. Researchers will track side effects and blood sugar control over one year. The goal is to see how the drug works in everyday life, not to cure diabetes…

This early-stage study tests a new medicine, NNC9733-0001, to see if it is safe and tolerable in healthy volunteers and people with type 2 diabetes. Participants receive either the study drug or a placebo as a single injection. The study lasts about 10 months and will monitor sid…

This study tests a new medicine called UBT251 to see if it is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either UBT251 or a placebo (dummy treatment) by chance. The main goals are to check for side effects and measure weight change…

This study tests the safety of a medicine called eptacog alfa for women in India who have severe bleeding after giving birth. About 64 women who do not respond to standard treatments will receive one or two doses of the drug. Researchers will monitor for side effects like blood c…

This study tests whether a new medicine called ziltivekimab can reduce plaque buildup in heart arteries after a heart attack. About 332 participants will receive either the drug or a placebo for 15 months. The goal is to see if the drug helps manage artery disease, but it is not …

This study tests a new medicine called CDR132L in 200 people with heart failure and an enlarged heart. The goal is to see if it can improve heart structure and function. Participants will receive either the study drug or a placebo for about 60 weeks. This is a Phase 2 trial, mean…

This study tests a new insulin called icodec that is taken just once a week, compared to the standard daily insulin glargine, in adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar as well as the daily one. About 877 people will take part fo…

This study tests if a once-weekly insulin shot (icodec) works as well as daily insulin shots for people with type 2 diabetes. About 586 adults who have not used insulin before will take either the weekly or a daily insulin for 13 months. The main goal is to see how well each cont…

This early-stage study tests a new medicine called NNC4005-0001 in 60 adults who are overweight and have extra fat in their liver. The goal is to see if the drug is safe and well-tolerated. Participants will receive either the active drug or a placebo, and the study lasts about 7…

This study follows people with sickle cell disease or thalassemia who have already taken etavopivat in a previous trial and benefited from it. Researchers want to understand the long-term safety and effectiveness of this experimental drug over up to five years. The study will tra…

This early-stage study tests a new medicine called NNC0581-0001 in 48 adults with fatty liver and possible liver inflammation. Participants receive either the drug or a placebo as a monthly injection for 3 months. The main goal is to check safety and how the body processes the dr…

This study will check how well a new insulin called insulin icodec controls blood sugar in people with type 1 diabetes who have never used it before. About 245 adults will take the insulin as their doctor prescribes, and researchers will track their blood sugar levels and satisfa…

This study tests a new medicine called CDR132L to see if it can improve heart structure and function in people with heart failure. About 200 participants will receive either the study drug or a placebo for around 60 weeks. The goal is to find a better way to manage this chronic c…

This study tests a new weekly injection called NNC0487-0111 for people who are overweight or obese and have type 2 diabetes. About 630 adults will receive either the active drug or a placebo to see if it safely helps with weight loss, waist size, blood sugar, and blood pressure. …

This phase 3 study tests whether a once-weekly injection called NNC0487-0111 is safe and effective for weight loss in adults with obesity. About 1,150 participants will receive either the active drug or a placebo for comparison. The main goal is to measure the percentage of body …

This study looks at whether combining two experimental weight-loss drugs (cagrilintide and NNC0480-0389) causes fewer stomach issues like nausea and vomiting compared to taking cagrilintide alone. About 100 women with overweight or obesity will receive both drugs in one period an…

This study tests a new drug called NNC0537-1482 to see if it is safe for people with heart failure. About 36 adults aged 40-75 will receive either the drug or a placebo by chance. The study lasts up to 64 days and focuses on side effects and how the drug moves through the body.

This study tests a once-weekly injection called NNC0487-0111 in 400 adults with overweight or obesity and knee osteoarthritis. The goal is to see if it helps with weight loss and reduces knee pain and stiffness. Participants receive either the active drug or a placebo by chance.

This early-stage study is testing a new medicine called NNC6989-0001 to see if it is safe for healthy people who are overweight or have obesity. About 96 participants will receive either the study drug or a placebo (a dummy treatment) by chance. The main goal is to check for any …

This study tests how eating before and after taking a new medicine called Inno8 affects its absorption in healthy men aged 18-45. Participants will fast overnight, take the drug, and then fast again for different periods. The goal is to find the best meal timing for future use in…

This study looks at how long people with obesity should fast and pause their GLP-1 medications (liraglutide or semaglutide) to ensure their stomach is empty after a high-fat meal. Researchers will measure stomach contents using ultrasound in 75 adults already taking these drugs. …

This study is for people with a rare heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers are testing a new drug, coramitug, to see how well it targets and removes these protein deposits. The study uses special PET/CT scans to track the drug …

This study will look back at medical records of 900 male hemophilia A patients in Iraq to see how doctors use the clotting medicine turoctocog alfa in everyday practice. The goal is to understand how often patients have bleeding episodes while on this treatment. No new treatments…